Company intelligence / Profile preview

Leman Cardiovascular

Morges, Vaud, Switzerland

Ownership: Private
Development stage: Other

Overview

Leman Cardiovascular has developed a third-generation biological heart valve with promising pre-clinical results, including improved hemodynamic performance, minimal energy loss, and 100% survival in animal studies at 90 days. However, there is no public evidence of progression to human clinical trials or commercialization.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Leman Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leman Cardiovascular.

Explore the full profile